Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Price, Quote, News and Overview

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

1.38  -0.03 (-2.13%)

CLLS Quote, Performance and Key Statistics

CELLECTIS - ADR

NASDAQ:CLLS (5/14/2025, 4:11:19 PM)

1.38

-0.03 (-2.13%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3
52 Week Low1.1
Market Cap138.40M
Shares100.29M
Float52.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04
IPO02-06 2007-02-06


CLLS short term performance overview.The bars show the price performance of CLLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

CLLS long term performance overview.The bars show the price performance of CLLS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CLLS is 1.38 USD. In the past month the price decreased by -5.48%. In the past year, price decreased by -53.85%.

CELLECTIS - ADR / CLLS Daily stock chart

CLLS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.28 313.89B
AMGN AMGEN INC 12.63 141.01B
GILD GILEAD SCIENCES INC 12.71 122.48B
VRTX VERTEX PHARMACEUTICALS INC N/A 108.27B
REGN REGENERON PHARMACEUTICALS 12.89 61.69B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.80B
ARGX ARGENX SE - ADR 90.68 32.50B
ONC BEIGENE LTD-ADR 5.46 23.71B
BNTX BIONTECH SE-ADR N/A 22.14B
NTRA NATERA INC N/A 20.57B
BIIB BIOGEN INC 7.61 17.64B
SMMT SUMMIT THERAPEUTICS INC N/A 16.90B

About CLLS

Company Profile

CLLS logo image Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Company Info

CELLECTIS - ADR

8, rue de la Croix Jarry

Paris ILE-DE-FRANCE 75013 FR

CEO: Andre Choulika

Employees: 219

CLLS Company Website

CLLS Investor Relations

Phone: 33181691600

CELLECTIS - ADR / CLLS FAQ

What is the stock price of CELLECTIS - ADR today?

The current stock price of CLLS is 1.38 USD. The price decreased by -2.13% in the last trading session.


What is the ticker symbol for CELLECTIS - ADR stock?

The exchange symbol of CELLECTIS - ADR is CLLS and it is listed on the Nasdaq exchange.


On which exchange is CLLS stock listed?

CLLS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CELLECTIS - ADR stock?

14 analysts have analysed CLLS and the average price target is 7.27 USD. This implies a price increase of 426.51% is expected in the next year compared to the current price of 1.38. Check the CELLECTIS - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CELLECTIS - ADR worth?

CELLECTIS - ADR (CLLS) has a market capitalization of 138.40M USD. This makes CLLS a Micro Cap stock.


How many employees does CELLECTIS - ADR have?

CELLECTIS - ADR (CLLS) currently has 219 employees.


What are the support and resistance levels for CELLECTIS - ADR (CLLS) stock?

CELLECTIS - ADR (CLLS) has a support level at 1.16 and a resistance level at 1.55. Check the full technical report for a detailed analysis of CLLS support and resistance levels.


Is CELLECTIS - ADR (CLLS) expected to grow?

The Revenue of CELLECTIS - ADR (CLLS) is expected to grow by 63.01% in the next year. Check the estimates tab for more information on the CLLS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CELLECTIS - ADR (CLLS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CELLECTIS - ADR (CLLS) stock pay dividends?

CLLS does not pay a dividend.


When does CELLECTIS - ADR (CLLS) report earnings?

CELLECTIS - ADR (CLLS) will report earnings on 2025-08-04.


What is the Price/Earnings (PE) ratio of CELLECTIS - ADR (CLLS)?

CELLECTIS - ADR (CLLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).


What is the Short Interest ratio of CELLECTIS - ADR (CLLS) stock?

The outstanding short interest for CELLECTIS - ADR (CLLS) is 0.61% of its float. Check the ownership tab for more information on the CLLS short interest.


CLLS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CLLS. When comparing the yearly performance of all stocks, CLLS is a bad performer in the overall market: 86.76% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CLLS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CLLS. The financial health of CLLS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CLLS Financial Highlights

Over the last trailing twelve months CLLS reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 45.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.12%
ROE -41.34%
Debt/Equity 0.65
Chartmill High Growth Momentum
EPS Q2Q%-325%
Sales Q2Q%85.13%
EPS 1Y (TTM)45.54%
Revenue 1Y (TTM)435.37%

CLLS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to CLLS. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -235.09% and a revenue growth 63.01% for CLLS


Ownership
Inst Owners20.91%
Ins Owners3.88%
Short Float %0.61%
Short Ratio0.83
Analysts
Analysts85.71
Price Target7.27 (426.81%)
EPS Next Y-235.09%
Revenue Next Year63.01%